

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO.

Y2428-00163

APPLICATION NO.

10/510,673

APPLICANT

Brogmann et al.

FILING DATE

May 23, 2005

GROUP

1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A06 4,126,684	11/21/1978	Robson et al.			
	A07 4,668,685	05/26/1987	Shami			
	A08 5,236,714	08/17/1993	Lee et al.			
	A09 6,258,042	07/10/2001	Factor et al.			
	A10 6,696,088	02/24/2004	Oshlack et al.			
	A11 2003/0178031	09/25/2003	DuPen et al.			
	A12 2007/0185146	08/09/2007	Fleischer et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
B14	2138593	03/30/1972	DE			
B15	1604666	12/14/2005	EP			
B16	1353815	05/22/1974	GB			
B17	1999/005960	02/11/1999	PCT			
B18	2001/058447	08/16/2001	PCT			
B19	2002/087512	11/07/2002	PCT			
B20	2002/092060	11/21/2002	PCT			
B21	2003/020124	03/13/2003	PCT			
B22	2003/073937	09/12/2003	PCT			
B23	2003/084504	10/16/2003	PCT			
B24	2003/084520	10/16/2003	PCT			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C09	Clark et al., "Symptom indexes to assess outcomes of treatment for early prostate cancer" <i>Medical Care</i> 39(10): 1118-1130 (October, 2001).
C10	Cohen, <i>Statistical Power Analyses for the Behavioral Sciences</i> (2 nd ed.) Hillsdale, NJ: Erlbaum (1988) ^{Table of contents only}
C11	Deyo RA et al., "Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation." <i>Cont. Clin. Trials</i> 12: 142S-158S (1991).
C12	Drossman DA et al., <i>Rome II: The Functional Gastrointestinal Disorders</i> (2 nd ed.) McLean, VA: Degnon Associates (2000) ^{Table of contents only}
C13	Guyatt et al., "Measuring change over time: assessing the usefulness of evaluative instruments" <i>J. Chronic Dis.</i> 40(2): 171-178 (1987).
C14	Guyatt et al., "Interpreting treatment effects in randomized trials" <i>Br. Med. J.</i> 316(7132): 690-693 (1998).
C15	Hays et al., "Assessing reliability and validity of measurement in clinical trials" in: Staquet et al., (eds.) <i>Quality of Life in Clinical Trials: Methods and Practice</i> Oxford: Oxford University Press (1998).
C08	Hussain, MA, "Improved buccal delivery of opioid analgesics and antagonists with bitterless prodrugs" <i>Pharm. Res.</i> 5(9): 615-618 (1988).
C16	Kazis et al., "Effects sizes for interpreting changes in health status" <i>Med. Care</i> 27(3 Suppl.): S178-S189 (1989).
C17	Leidy et al., "Recommendations for evaluating the validity of quality of life claims for labelling and promotion" <i>Value in Health</i> 2(2): 113-127 (1999).

/Carolynne Helm/

04/16/2010

DM22070915.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.H./

	C18	Norman et al., "Interpretation of changes in health-related quality of life. The remarkable universality of half a standard deviation" <u>Med. Care</u> 41: 582-592 (2003).		
	C19	Nunnally et al., <u>Psychometric Theory</u> (3 rd ed.) NY: McGraw-Hill (1994). Table of contents only		
	C20	Revicki et al., "Recommendation on health-related quality of life research to support labelling and promotional claims in the United States" <u>QOL Research</u> 9(8): 887-900 (2000).		
	C21	Wyrwich et al., "Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life" <u>J. Clin. Epidemiol.</u> 52: 861-873 (1991).		
EXAMINER		/Caralynne Helm/	DATE CONSIDERED	04/16/2010
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				